Mylostat 500mg Capsule 7pcs
Mylostat 500mg Capsule 7pcs Original price was: 105.00৳ .Current price is: 99.75৳ .
Back to products
Navigo 40 Infusion | 40mg Vial
Navigo 40 Infusion | 40mg Vial Original price was: 40,000.00৳ .Current price is: 39,200.00৳ .
-2%
Click to enlarge

Nab-Xelpac IV Infusion

SKU: 474

Manufacturer: Beacon Pharmaceuticals Ltd.

Generic: Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel]

Type: Bottle

Pack Size: 1 Pc

Apple Shopping Event

Hurry and get discounts on all Apple devices up to 20%

Sale_coupon_15

Original price was: 25,000.00৳ .Current price is: 24,500.00৳ .

Compare
Add to wishlist

Description

Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel]

Metastatic Breast Cancer:

  • Used for treatment after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
  • Prior treatment should include an anthracycline unless contraindicated.

Non-Small Cell Lung Cancer (NSCLC):

  • First-line treatment of locally advanced or metastatic NSCLC, in combination with carboplatin, for patients not eligible for curative surgery or radiation therapy.

Adenocarcinoma of the Pancreas:

  • First-line treatment for metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

Used as a treatment for cancers including metastatic breast cancer, NSCLC, and advanced pancreatic adenocarcinoma. It works by interfering with the normal function of microtubules during cell division, effectively stopping cancer cell proliferation.
Metastatic Breast Cancer:

  • Dose: 260 mg/m², IV infusion over 30 minutes every 3 weeks.

Non-Small Cell Lung Cancer:

  • Dose: 100 mg/m², IV infusion over 30 minutes on Days 1, 8, and 15 of a 21-day cycle.
  • Administer carboplatin on Day 1 after Nab-Xelpac.

Adenocarcinoma of the Pancreas:

  • Dose: 125 mg/m², IV infusion over 30–40 minutes on Days 1, 8, and 15 of a 28-day cycle.
  • Administer gemcitabine immediately after Nab-Xelpac.

Hepatic Impairment:

  • Adjust the dose for moderate to severe hepatic impairment.
  • Do not administer to patients with total bilirubin >5x ULN or AST >10x ULN.

Always handle and administer Nab-Xelpac under the supervision of qualified oncology professionals in a clinical setting. Proper monitoring and adherence to protocols are essential to ensure patient safety and treatment efficacy.